Skip to main content

Advertisement

SpringerLink
Log in

Replicating poxviruses for human cancer therapy

  • Minireview
  • Published:
Journal of Microbiology Aims and scope Submit manuscript

Abstract

Naturally occurring oncolytic viruses are live, replication-proficient viruses that specifically infect human cancer cells while sparing normal cell counterparts. Since the eradication of smallpox in the 1970s with the aid of vaccinia viruses, the vaccinia viruses and other genera of poxviruses have shown various degrees of safety and efficacy in pre-clinical or clinical application for human anti-cancer therapeutics. Furthermore, we have recently discovered that cellular tumor suppressor genes are important in determining poxviral oncolytic tropism. Since carcinogenesis is a multi-step process involving accumulation of both oncogene and tumor suppressor gene abnormalities, it is interesting that poxvirus can exploit abnormal cellular tumor suppressor signaling for its oncolytic specificity and efficacy. Many tumor suppressor genes such as p53, ATM, and RB are known to play important roles in genomic fidelity/maintenance. Thus, tumor suppressor gene abnormality could affect host genomic integrity and likely disrupt intact antiviral networks due to accumulation of genetic defects, which would in turn result in oncolytic virus susceptibility. This review outlines the characteristics of oncolytic poxvirus strains, including vaccinia, myxoma, and squirrelpox virus, recent progress in elucidating the molecular connection between oncogene/tumor suppressor gene abnormalities and poxviral oncolytic tropism, and the associated preclinical/clinical implications. I would also like to propose future directions in the utility of poxviruses for oncolytic virotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Alkassar, M., Gärtner, B., Roemer, K., Graesser, F., Rommelaere, J., Kaestner, L., Haeckel, I., and Graf, N. 2011. The combined effects of oncolytic reovirus plus Newcastle disease virus and reovirus plus parvovirus on U87 and U373 cells in vitro and in vivo. J. Neurooncol. 104, 715–727.

    Article  PubMed  Google Scholar 

  • Amato, R.J. and Stepankiw, M. 2012. Evaluation of MVA-5T4 as a novel immunotherapeutic vaccine in colorectal, renal and prostate cancer. Future Oncol. 8, 231–237.

    Article  CAS  PubMed  Google Scholar 

  • Antoine, G., Scheiflinger, F., Dorner, F., and Falkner, F.G. 1998. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 244, 365–396.

    Article  CAS  PubMed  Google Scholar 

  • Autio, K., Knuuttila, A., Kipar, A., Ahonen, M., Parviainen, S., Diaconu, I., Kanerva, A., Hakonen, T., Vähä-Koskela, M., and Hemminki, A. 2014. Anti-tumour activity of oncolytic Western Reserve vaccinia viruses in canine tumour cell lines, xenografts, and fresh tumour biopsies. Vet. Comp. Oncol. In press.

    Google Scholar 

  • Baxby, D. 1977. The origins of vaccinia virus. J. Infect. Dis. 136, 453–455.

    Article  CAS  PubMed  Google Scholar 

  • Bearcroft, W.G. and Jamieson, M.F. 1958. An outbreak of subcutaneous tumours in rhesus monkeys. Nature 182, 195–196.

    Article  CAS  PubMed  Google Scholar 

  • Brandt, T., Heck, M.C., Vijaysri, S., Jentarra, G.M., Cameron, J.M., and Jacobs, B.L. 2005. The N-terminal domain of the vaccinia virus E3L-protein is required for neurovirulence, but not induction of a protective immune response. Virology 333, 263–270.

    Article  CAS  PubMed  Google Scholar 

  • Brandt, T.A. and Jacobs, B.L. 2001. Both carboxy- and amino-terminal domains of the vaccinia virus interferon resistance gene, E3L, are required for pathogenesis in a mouse model. J. Virol. 75, 850–856.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Buller, R.M., Smith, G.L., Cremer, K., Notkins, AL., and Moss, B. 1985. Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype. Nature 317, 813–815.

    Article  CAS  PubMed  Google Scholar 

  • Carroll, M.W., Overwijk, W.W., Chamberlain, R.S., Rosenberg, S.A., Moss, B., and Restifo, N.P. 1997. Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model. Vaccine 15, 387–394.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Carroll, B., Russell, P., Gurnell, J., Nettleton, P., and Sainsbury, A.W. 2009. Epidemics of squirrel pox virus disease in red squirrels (Sciurus vulgaris): temporal and serological findings. Epidemiol. Infect. 137, 257–265.

    Article  CAS  PubMed  Google Scholar 

  • Chan, W.M. and McFadden, G. 2014. Oncolytic Poxviruses. Annu. Rev. Virol. 1, 191–214.

    Article  Google Scholar 

  • Chen B., Timiryasova, T.M., Haghighat, P., Andres, M.L., Kajioka, E.H., Dutta-Roy, R., Gridley, D.S., and Fodor, I. 2001. Lowdose vaccinia virus-mediated cytokine gene therapy of glioma. J. Immunother. 24, 46–57.

    Article  CAS  PubMed  Google Scholar 

  • Collins, L.M., Warnock, N.D., Tosh, D.G., McInnes, C., Everest, D., Montgomery, W.I., Scantlebury, M., Marks, N., Dick, J.T., and Reid, N. 2014. Squirrelpox virus: assessing prevalence, transmission and environmental degradation. PLoS One 9, e89521.

    Article  PubMed Central  PubMed  Google Scholar 

  • Coschi, C.H. and Dick, F.A. 2012. Chromosome instability and deregulated proliferation: an unavoidable duo. Cell Mol. Life Sci. 69, 2009–2024.

    Article  CAS  PubMed  Google Scholar 

  • Downie, A.W., Taylor-Robinson, C.H., Caunt, A.E., Nelson, G.S., Manson-Bahr, P.E., and Matthews, T.C. 1971. Tanapox: a new disease caused by a pox virus. Br. Med. J. 1, 363–368.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Drexler, I., Antunes, E., Schmitz, M., Wölfel, T., Huber, C., Erfle, V., Rieber, P., Theobald, M., and Sutter, G. 1999. Modified vaccinia virus Ankara for delivery of human tyrosinase as melanoma-associated antigen: induction of tyrosinase- and melanoma- specific human leukocyte antigen A*0201-restricted cytotoxic T cells in vitro and in vivo. Cancer Res. 59, 4955–4963.

    CAS  PubMed  Google Scholar 

  • Duff, J.P., Scott, A., and Keymer, I.F. 1996. Parapox virus infection of the grey squirrel. Vet. Rec. 138, 527.

    CAS  PubMed  Google Scholar 

  • Ellner, P.D. 1998.Smallpox: gone but not forgotten. Infection 26, 263–269.

    Article  CAS  PubMed  Google Scholar 

  • Espana, C. 1971. Review of some outbreaks of viral disease in captive nonhuman primates. Lab. Anim. Sci. 21, 1023–1031.

    CAS  PubMed  Google Scholar 

  • Evgin, L., Vähä-Koskela, M., Rintoul, J., Falls, T., Le Boeuf, F., Barrett, J.W., Bell, J.C., and Stanford, M.M. 2010. Potent oncolytic activity of raccoonpox virus in the absence of natural pathogenicity. Mol. Ther. 18, 896–902.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Fenner, F. 1983. The Florey lecture, 1983. Biological control, as exemplified by smallpox eradication and myxomatosis. Proc. R Soc. Lond B Biol. Sci. 218, 259–285.

    Article  CAS  PubMed  Google Scholar 

  • Fenner, F. 2010. Deliberate introduction of the European rabbit, Oryctolagus cuniculus, into Australia. Rev. Sci. Tech. 29, 103–111.

    CAS  PubMed  Google Scholar 

  • Gentschev, I., Patil, S.S., Petrov, I., Cappello, J., Adelfinger, M., and Szalay, A.A. 2014. Oncolytic virotherapy of canine and feline cancer. Viruses 6, 2122–2137.

    Article  PubMed Central  PubMed  Google Scholar 

  • Gholami, S., Marano, A., Chen, N.G., Aguilar, R.J., Frentzen, A, Chen, C.H., Lou, E., Fujisawa, S., Eveno, C., Belin, L., et al. 2014. A novel vaccinia virus with dual oncolytic and anti-angiogenic therapeutic effects against triple-negative breast cancer. Breast Cancer Res. Treat. 148, 489–499.

    Article  CAS  PubMed  Google Scholar 

  • Gnant, M.F., Puhlmann, M., Alexander, H.R. Jr, and Bartlett, D.L. 1999. Systemic administration of a recombinant vaccinia virus expressing the cytosine deaminase gene and subsequent treatment with 5-fluorocytosine leads to tumor-specific gene expression and prolongation of survival in mice. Cancer Res. 59, 3396–3403.

    CAS  PubMed  Google Scholar 

  • Gomella, L.G., Mastrangelo, M.J., McCue, P.A., Maguire, H.C. Jr, Mulholland, S.G., and Lattime, E.C. 2001. Phase i study of intravesical vaccinia virus as a vector for gene therapy of bladder cancer. J. Urol. 166, 1291–1295.

    Article  CAS  PubMed  Google Scholar 

  • Gómez, C.E., Perdiguero, B., García-Arriaza, J., and Esteban, M. 2103. Clinical applications of attenuated MVA poxvirus strain. Expert. Rev. Vaccines 12, 1395–1416.

  • Gurnell, J. 1996. The grey squirrel in Britain: problems for management and lessons for Europe, pp. 67–81. In Mathias, M.L., Santos-Reis, M., Amori, G., Libois, R., Mitchell-Jones, A., et al. (eds.). European Mammals, Proceedings of the I European Congress of Mammalogy. Museu Bocage.

    Google Scholar 

  • Halsell, J.S., Riddle, J.R., Atwood, J.E., Gardner, P., Shope, R., Poland, G.A., Gray, G.C., Ostroff, S., Eckart, R.E., Hospenthal, D.R., et al. 2003. Myopericarditis following smallpox vaccination among vaccinia-naive US military personnel. JAMA 289, 3283–3289.

    Article  PubMed  Google Scholar 

  • Hartkopf, A.D., Fehm, T., Wallwiener, D., and Lauer, U. 2011. Oncolytic virotherapy of gynecologic malignancies. Gynecol. Oncol. 120, 302–310.

    Article  PubMed  Google Scholar 

  • Hashizume, S. 2004. Develoment of the attenuated Smallpox vaccine, LC16m8, produced by cell culture (translated from Japanese). Modern. Media 50, 4–9.

    Google Scholar 

  • Hayes, R.A. and Richardson, B.J. 2001. Biological control of the rabbit in Australia: lessons not learned? Trends Microbiol. 9, 459–460.

    Article  CAS  PubMed  Google Scholar 

  • Heo, J., Reid, T., Ruo, L., Breitbach, C.J., Rose, S., Bloomston, M., Cho, M., Lim, H.Y., Chung, H.C., Kim, C.W., et al. 2013. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat. Med. 19, 329–336.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Herman, Y.F. 1964. Isolation and characterization of a naturally occurring poxvirus of raccoons [abstract]. 64th Bacteriological Proceedings, American Society for Microbiology. p. 117.

    Google Scholar 

  • Hiley, C.T., Yuan, M., Lemoine, N.R., and Wang, Y. 2010. Lister strain vaccinia virus, a potential therapeutic vector targeting hypoxic tumours. Gene Ther. 17, 281–287.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Hikichi, M., Kidokoro, M., Haraguchi, T., Iba, H., Shida, H., Tahara, H., and Nakamura, T. 2011. MicroRNA regulation of glycoprotein B5R in oncolytic vaccinia virus reduces viral pathogenicity without impairing its antitumor efficacy. Mol. Ther. 19, 1107–1115.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Hochstein-Mintzel, V., Hanichen, T., Huber, H.C., and Stickl, H. 1975. Vaccine- and variola-protective effect of the modified vaccinia strain MVA in intramuscular immunization [in German]. Zentralbl Bakteriol [Orig A] 975, 283–297.

    Google Scholar 

  • Housawi, F.M., Roberts, G.M., Gilray, J.A., Pow, I., Reid, H.W., Nettleton, P.F., Sumption, K.J., Hibma, M.H., and Mercer, A.A. 1998. The reactivity of monoclonal antibodies against orf virus with other parapoxviruses and the identification of a 39 kDa immunodominant protein. Arch. Virol. 143, 2289–2303.

    Article  CAS  PubMed  Google Scholar 

  • Hu, Y., Lee, J., McCart, J.A., Xu, H., Moss, B., Alexander, H.R., and Bartlett, D.L. 2001. Yaba-like disease virus: an alternative replicating poxvirus vector for cancer gene therapy. J. Virol. 75, 10300–10308.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Hung, C.F., Tsai, Y.C., He, L., Coukos, G., Fodor, I., Qin, L., Levitsky, H., and Wu, T.C. 2007. Vaccinia virus preferentially infects and controls human and murine ovarian tumors in mice. Gene Ther. 14, 20–29.

    Article  CAS  PubMed  Google Scholar 

  • Jacobs, B.L., Langland, J.O., Kibler, K.V., Denzler, K.L., White, S.D., Holechek, S.A., Wong, S., Huynh, T., and Baskin, C.R. 2009. Vaccinia virus vaccines: past, present and future. Antiviral Res. 84, 1–13.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Johnston, J.B., Barrett, J.W., Chang, W., Chung, C.S., Zeng, W., Masters, J., Mann, M., Wang, F., Cao, J., and McFadden, G. 2003. Role of the serine-threonine kinase PAK-1 in myxoma virus replication. J. Virol. 77, 5877–5888.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Kaplan, C. 1989. Vaccinia virus: a suitable vehicle for recombinant vaccines? Arch. Virol. 106, 127–139.

    Article  CAS  PubMed  Google Scholar 

  • Katsafanas, G.C. and Moss, B. 2004. Vaccinia virus intermediate stage transcription is complemented by Ras-GTPase-activating protein SH3 domain-binding protein (G3BP) and cytoplasmic activation/proliferation-associated protein (p137) individually or as a heterodimer. J. Biol. Chem. 279, 52210–52217.

    Article  CAS  PubMed  Google Scholar 

  • Kerr, P.J., Ghedin, E., DePasse, J.V., Fitch, A., Cattadori, I.M., Hudson, P.J., Tscharke, D.C., Read, A.F., and Holmes, E.C. 2012. Evolutionary history and attenuation of myxoma virus on two continents. PLoS Pathog. 8, e1002950.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Kenner, J., Cameron, F., Empig, C., Jobes, D.V., and Gurwith, M. 2006. LC16m8: an attenuated smallpox vaccine. Vaccine 24, 7009–7022.

    Article  CAS  PubMed  Google Scholar 

  • Kilham, L., Herman, C.M., and Fisher, E.R. 1953. Naturally occurring fibromas of grey squirrels related to Shope’s rabbit fibroma. Proc. Soc. Exp. Biol. Med. 82, 298–301.

    Article  CAS  PubMed  Google Scholar 

  • Kim, M., Ahn, J.S., Yun, C.O., and Kim, BY. 2014a. Squirrel poxvirus as a novel oncolytic agent. The 40th annual meeting of Korean Cancer Association. Seoul Korea. June 20.

    Google Scholar 

  • Kim, M., Ahn, J.S., Yun, C.O., and Kim, B.Y. 2014b. Therapeutic or preventive pharmacological composition of squirrelpox virus for anticancer therapeutics (Translated in Korean). Korean patent No.: 10-1370620 Date of Patent grant: Feb 27, 2014.

    Google Scholar 

  • Kim, M., Egan, C., Alain, T., Urbanski, S.J., Lee, P.W., Forsyth, P.A., and Johnston, R.N. 2007. Acquired resistance to reoviral oncolysis in Ras-transformed fibrosarcoma cells. Oncogene 26, 4124–4134.

    Article  CAS  PubMed  Google Scholar 

  • Kim, M. and Johnston, R.N. 2014. Tumor suppressor-based susceptibility of hyperproliferative cells to oncolytic viral therapy. Chinese patent No.: 200980126543.5 Date of Patent grant: July 30, 2014.

    Google Scholar 

  • Kim, M., Madlambayan, G.J., Rahman, M.M., Smallwood, S.E., Meacham, A.M., Hosaka, K., Scott, E.W., Cogle, C.R., and Mc-Fadden, G. 2009. Myxoma virus targets primary human leukemic stem and progenitor cells while sparing normal hematopoietic stem and progenitor cells. Leukemia 23, 2313–2317.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Kim, M., Williamson, C.T., Prudhomme, J., Bebb, D.G., Riabowol, K., Lee, P.W., Lees-Miller, S.P., Mori, Y., Rahman, M.M., Mc-Fadden, G., et al. 2010. The viral tropism of two distinct oncolytic viruses, reovirus and myxoma virus, is modulated by cellular tumor suppressor gene status. Oncogene 29, 3990–3996.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Knight, J.C., Novembre, F.J., Brown, D.R., Goldsmith, C.S., and Esposito, J.J. 1989. Studies on Tanapox virus. Virology 172, 116–124.

    Article  CAS  PubMed  Google Scholar 

  • Kochneva, G.V., Sivolobova, G.F., Iudina, K.V., Babkin, I.V., Chumakov, P.M., and Netesov, S.V. 2012. Oncolytic poxviruses. Mol. Gen. Mikrobiol. Virusol. 1, 8–15.

    PubMed  Google Scholar 

  • Lane, J.M. and Goldstein, J. 2003. Adverse events occurring after smallpox vaccination. Semin. Pediatr. Infect. Dis. 14, 189–195.

    Article  PubMed  Google Scholar 

  • Larocca, C. and Schlom, J. 2011. Viral vector-based therapeutic cancer vaccines. Cancer J. 17, 359–371.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Le Boeuf, F., Diallo, J.S., McCart, J.A., Thorne, S., Falls, T., Stanford, M., Kanji, F., Auer, R., Brown, C.W., Lichty, B.D., et al. 2010. Synergistic interaction between oncolytic viruses augments tumor killing. Mol. Ther. 18, 888–895.

    Article  PubMed Central  PubMed  Google Scholar 

  • Liu, Y.P., Wang, J., Avanzato, V.A., Bakkum-Gamez, J.N., Russell, S.J., Bell, J.C., and Peng, K.W. 2014. Oncolytic vaccinia virotherapy for endometrial cancer. Gynecol. Oncol. 132, 722–729.

    Article  PubMed Central  PubMed  Google Scholar 

  • Lun, X., Yang, W., Alain, T., Shi, Z.Q., Muzik, H., Barrett, J.W., McFadden, G., Bell, J., Hamilton, M.G., Senger, D.L., et al. 2005. Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas. Cancer Res. 65, 9982–9990.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Mathew, E., Sanderson, C.M., Hollinshead, M., and Smith, G.L. 1998. The extracellular domain of vaccinia virus protein B5R affects plaque phenotype, extracellular enveloped virus release, and intracellular actin tail formation. J. Virol. 72, 2429–2438.

    PubMed Central  CAS  PubMed  Google Scholar 

  • Mastrangelo, M.J., Maguire, H.C. Jr, Eisenlohr, L.C., Laughlin, C.E., Monken, C.E., McCue, P.A., Kovatich, A.J., and Lattime, E.C. 1999. Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther. 6, 409–422.

    Article  CAS  PubMed  Google Scholar 

  • Mayr, A. 2003. Smallpox vaccination and bioterrorism with pox viruses. Comp. Immunol. Microbiol. Infect Dis. 26, 423–430.

    Article  PubMed  Google Scholar 

  • Mayr, A., Hochstein-Mintzel, V., and Stickl, H. 1975. Passage history, properties, and applicability of the attenuated vaccinia virus strain MVA [in German]. Infectio. 3, 6–14.

    Article  Google Scholar 

  • Mayr, A., Stickl, H., Muller, H.K., Danner, K., and Singer, H. 1978. The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism [in German]. Zentralbl Bakteriol [B] 167, 375–390.

    CAS  Google Scholar 

  • McCart, J.A., Puhlmann, M., Lee, J., Hu, Y., Libutti, S.K., Alexander, H.R., and Bartlett, D.L. 2000. Complex interactions between the replicating oncolytic effect and the enzyme/prodrug effect of vaccinia-mediated tumor regression. Gene Ther. 7, 1217–1223.

    Article  CAS  PubMed  Google Scholar 

  • McCart, J.A., Ward, J.M., Lee, J., Hu, Y., Alexander, H.R., Libutti, S.K., Moss, B., and Bartlett, D.L. 2001. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res. 61, 8751–8757.

    CAS  PubMed  Google Scholar 

  • McCurdy, L.H., Rutigliano, J.A., Johnson, T.R., Chen, M., and Graham, B.S. 2004. Modified vaccinia virus Ankara immunization protects against lethal challenge with recombinant vaccinia virus expressing murine interleukin-4. J. Virol. 78, 12471–12479.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • McFadden, G. 2005. Poxvirus tropism. Nat. Rev. Microbiol. 3, 201–213.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • McInnes, C.J., Wood, A.R., Thomas, K., Sainsbury, A.W., Gurnell, J., Dein, F.J., and Nettleton, P.F. 2006. Genomic characterization of a novel poxvirus contributing to the decline of the red squirrel (Sciurus vulgaris) in the UK. J. Gen. Virol. 87, 2115–2125.

    Article  CAS  PubMed  Google Scholar 

  • Mell, L.K., Brumund, K.T., Advani, S.J., Onyeama, S., Daniels, G.A., Weisman, R.A., Martin, P., and Szalay, A.A. 2014. Phase 1 trial of attenuated vaccinia virus (GL-ONC1) delivered intravenously with concurrent cisplatin and radiation therapy in patients with locoregionally advanced head-and-neck carcinoma. Inl. J. Radiation Oncology · Biology · Physics. 88, 477–478.

    Article  Google Scholar 

  • Morikawa, S., Sakiyama, T., Hasegawa, H., Saijo, M., Maeda, A., Kurane, I., Maeno, G., Kimura, J., Hirama, C., Yoshida, T., et al. 2005. An attenuated LC16m8 smallpox vaccine: analysis of fullgenome sequence and induction of immune protection. J. Virol. 79, 11873–11891.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Moss B. 2013. Poxviridae, pp. 3292–3809. In Fields, B.N., Knipe, D.M., and Howley, P.M. (eds.), Fields Virology, Lippincott-Raven, Philadelphia, USA.

  • Nalca, A. and Zumbrun, E.E. 2010. ACAM2000: the new smallpox vaccine for United States Strategic National Stockpile. Drug Des. Devel. Ther. 4, 71–79.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Opgenorth, A., Graham, K., Nation, N., Strayer, D., and McFadden, G. 1992. Deletion analysis of two tandemly arranged virulence genes in myxoma virus, M11L and myxoma growth factor. J. Virol. 66, 4720–4731.

    PubMed Central  CAS  PubMed  Google Scholar 

  • Park, B.H., Hwang, T., Liu, T.C., Sze, D.Y., Kim, J.S., Kwon, H.C., Oh, S.Y., Han, S.Y., Yoon, J.H., Hong, S.H., et al. 2008. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol. 9, 533–542.

    Article  CAS  PubMed  Google Scholar 

  • Parato, K.A., Senger, D., Forsyth, P.A., and Bell, J.C. 2005. Recent progress in the battle between oncolytic viruses and tumours. Nat. Rev. Cancer 5, 965–976.

    Article  CAS  PubMed  Google Scholar 

  • Parviainen, S., Ahonen, M., Diaconu, I., Kipar, A., Siurala, M., Vähä-Koskela, M., Kanerva, A., Cerullo, V., and Hemminki, A. 2015. GMCSF-armed vaccinia virus induces an antitumor immune response. Int. J. Cancer 136, 1065–1072.

    Article  CAS  PubMed  Google Scholar 

  • Puhlmann, M., Brown, C.K., Gnant, M., Huang, J., Libutti, S.K., Alexander, H.R., and Bartlett, D.L. 2000. Vaccinia as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutant. Cancer Gene Ther. 7, 66–73.

    Article  CAS  PubMed  Google Scholar 

  • Regnery, D.C. 1971. The epidemic potential of Brazilian myxoma virus (Lausanne strain) for three species of North American cottontails. Am. J. Epidemiol. 94, 514–519.

    CAS  PubMed  Google Scholar 

  • Roberts, M.S., Lorence, R.M., Groene, W.S., and Bamat, M.K. 2006. Naturally oncolytic viruses. Curr. Opin. Mol. Ther. 8, 314–321.

    PubMed  Google Scholar 

  • Rosenthal, S.R., Merchlinsky, M., Kleppinger, C., and Goldenthal, K.L. 2001. Developing new smallpox vaccines. Emerg. Infect. Dis. 7, 920–926.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Russell, S.J., Peng, K.W., and Bell, J.C. 2012. Oncolytic virotherapy. Nat. Biotechnol. 10, 658–670.

    Article  Google Scholar 

  • Sainsbury, A.W., Nettleton, P., Gilray, J., and Gurnell, J. 2000. Grey squirrels have high seroprevalence to a parapoxvirus associated with deaths in red squirrels. Anim. Conserv. 3, 229–233.

    Article  Google Scholar 

  • Stickl, H., Hochstein-Mintzel, V., Mayr, A., Huber, H.C., Schafer, H., and Holzner, A. 1974. MVA vaccination against smallpox: clinical trials with an attenuated live vaccinia virus strain (MVA) [in German]. Dtsch. Med. Wochenschr 99, 2386–2392.

    Article  CAS  PubMed  Google Scholar 

  • Strong, J.E., Coffey, M.C., Tang, D., Sabinin, P., and Lee, P.W. 1998. The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J. 17, 3351–3362.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Sutter, G. and Moss, B. 1992. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl. Acad. Sci. USA 89, 10847–10851.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Sypula, J., Wang, F., Ma, Y., Bell, J., and McFadden, G. 2004. Myxoma virus tropism in human tumor cells. Gene Ther. Mol. Biol. 8, 103–114.

    Google Scholar 

  • Thomas, E.K., Palmer, E.L., Obijeski, J.F., and Nakano, J.H. 1975. Further characterization of Raccoonpox virus. Arch. Virol. 49, 217–227.

    Article  CAS  PubMed  Google Scholar 

  • Thorne, S.H., Hwang, T.H., O’Gorman, W.E., Bartlett, D.L., Sei, S., Kanji, F., Brown, C., Werier, J., Cho, J.H., Lee, D.E., et al. 2007. Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963. J. Clin. Invest. 117, 3350–3358.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Timiryasova, T.M., Li, J., Chen, B., Chong, D., Langridge, W.H., Gridley, D.S., and Fodor, I. 1999. Antitumor effect of vaccinia virus in glioma model. Oncol. Res. 11, 133–144.

    CAS  PubMed  Google Scholar 

  • Tompkins, D.M., Sainsbury, A.W., Nettleton, P., Buxton, D., and Gurnell, J. 2002. Parapoxvirus causes a deleterious disease in red squirrels associated with UK population declines. Proc. R Soc. Lond B Biol. Sci. 269, 529–533.

    Article  Google Scholar 

  • Wang, G., Barrett, J.W., Stanford, M., Werden, S.J., Johnston, J.B., Gao, X., Sun, M., Cheng, J.Q., and McFadden, G. 2006. Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor. Proc. Natl. Acad. Sci. USA 103, 4640–4645.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Wilkinson, L. 1982. Jenner’s smallpox vaccine. The riddle of vaccinia virus and its origin. Med. Hist. 26, 94–95.

    Article  PubMed Central  Google Scholar 

  • Zeh, H.J., Downs-Canner, S., McCart, J.A., Guo, Z.S., Rao, U.N., Ramalingam, L., Thorne, S.H., Jones, H.L., Kalinski, P., Wieckowski, E., et al. 2015. First-in-man study of western reserve strain oncolytic vaccinia virus: safety, systemic spread, and antitumor activity. Mol. Ther. 23, 202–214.

    Article  CAS  PubMed  Google Scholar 

  • Zemp, F.J., McKenzie, B.A., Lun, X., Reilly, K.M., McFadden, G., Yong, V.W., and Forsyth, P.A. 2014. Cellular factors promoting resistance to effective treatment of glioma with oncolytic myxoma virus. Cancer Res. 74, 7260–7273.

    Article  CAS  PubMed  Google Scholar 

  • Zhang, Q., Yu, Y.A., Wang, E., Chen, N., Danner, R.L., Munson, P.J., Marincola, F.M., and Szalay, A.A. 2007. Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus. Cancer Res. 67, 10038–10046.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Science, Dankook University College of Medicine, Cheonan, 330-714, Republic of Korea

    Manbok Kim

Authors
  1. Manbok Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Manbok Kim.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kim, M. Replicating poxviruses for human cancer therapy. J Microbiol. 53, 209–218 (2015). https://doi.org/10.1007/s12275-015-5041-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12275-015-5041-4

Keywords

Search

Navigation